Rapidly Adaptable Nanotherapeutics

Period of Performance: 04/14/2015 - 08/31/2016

$2.23MM

Phase 2 SBIR

Recipient Firm

Techulon
2200 Kraft Drive Suite 1425
Blacksburg, VA 24060
Firm POC
Principal Investigator

Abstract

Infections caused by drug resistant bacteria create a $30b problem for the healthcare industry. Techulon has developed a Rapidly Adaptable NanoTherapeutic (RANT) approach to address this problem, which utilizes genomic targeting, on-demand synthesis, and nanotherapeutic delivery. Component feasibility studies conducted during Phase I demonstrated successful targeting and inhibition levels in methicillin-resistant Staphylococcus aureus (MRSA), a pervasive infectious bacteria acquired in hospitals and problematic for military wound healing. The Phase II work is designed to demonstrate in vivo validation of Techulon?s nanotherapeutic platform by establishing safety parameters and demonstrating efficacy in murine-infection models. Optimizing the response time of RANT is emphasized in the study plan. The research objectives for Phase II include system integration of proven components and developing agents against other pernicious infections in military hospitals, including Acinetobacter baumannii and Pseudomonas aeruginosa, to demonstrate the platform flexibility. Regulatory approval strategy is being developed and deployable-GMP production requirements will be established. Commercialization opportunities have been identified and the company has secured funds to address transition of the technology to broad military applications such as wound healing and burn trauma. The platform is also applicable to homeland defense applications such as unknown bio-terror threats. Commercial opportunities include clinical applications for hospital infections.